Vectura Breathes Easy As It Enters Eventful 2019
With a steady stream of royalties coming in from Flutiform and Ultibro and a decent pipeline of innovative respiratory drugs and generics, Vectura has presented a promising update for the year ahead.
You may also be interested in...
Vectura and Hikma could have generic versions of GSK's Ellipta portfolio ready for marketing when patent protection expires.
FDA issued a complete response letter for Hikma's ANDA to market a generic version of GSK's Advair, the second application to be rejected by FDA.
The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.